20-F/A: Altamira Therapeutics Amends 20-F Filing to Correct Accounting Firm Report Date

Altamira Therapeutics files an amendment to its 20-F annual report solely to correct the date of the independent auditor's report and include certifications from the CEO and CFO.

Summary

• Altamira Therapeutics has filed Amendment No. 1 to its Annual Report on Form 20-F for the year ended December 31, 2023.
• The amendment solely corrects the date of the Report of Independent Registered Public Accounting Firm of Deloitte AG on page F-2.
• The filing also includes certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.
• No other changes have been made to the original Form 20-F, and the amendment does not modify, amend, or update the financial or other information contained in the original filing.
• The amendment does not reflect any events that have occurred on or after the original filing date of April 10, 2024.
• The company has not revised forward-looking statements to reflect events that occurred or facts that became known after the original filing date.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The sentiment is neutral.

Positives

• The company is taking steps to ensure accurate financial reporting by correcting the error in the original filing.
• The inclusion of CEO and CFO certifications reinforces accountability and compliance with regulatory requirements.

Future Outlook

The document does not revise any forward-looking statements made in the original Form 20-F.

Industry Context

This is a standard regulatory filing update and doesn't provide specific insights into industry trends.

Key Dates

Keywords

20-F/A, amendment, annual report, Altamira Therapeutics, auditor report, certifications, Sarbanes-Oxley